Ready to discover a stock that could supercharge your portfolio? While no investment is without risk, one company stands out as a potential long-term winner. Let's dive into a growth stock poised to make waves in the coming years.
I'm not a huge fan of the term "growth stock" either. After all, isn't the goal of every investment to see your money flourish? However, in the financial world, growth stocks are those that are expected to grow at an above-average rate, potentially outperforming the broader market. And I have a favorite that fits that bill perfectly.
My top growth stock pick for this month is one I've held for several years, and I believe it's set to deliver substantial returns over the long haul. This company has three primary avenues for expansion, making it a compelling investment.
First, let's look at Vertex Pharmaceuticals (VRTX), a major player in the biotech world. Its cystic fibrosis (CF) franchise is a significant growth driver. Vertex has several approved CF therapies, but Kaftrio/Trikafta is the clear frontrunner, generating a whopping 86% of the company's total revenue in the second quarter of 2025. But here's where it gets controversial... even though it's a leader in the CF market, Kaftrio/Trikafta's sales only increased by 4% year-over-year in Q2. How can CF be Vertex's easiest path to growth? The key is Alyftrek, a newer CF therapy approved by the FDA in December 2024. This drug is expected to replace much of Kaftrio/Trikafta's sales because it is more effective and easier to take. While Alyftrek won't dramatically increase Vertex's CF revenue, it will boost profits because it has lower royalty burdens.
Second, Vertex is expanding beyond CF with products like Casgevy, the first approved CRISPR gene editing therapy, which treats sickle cell disease and transfusion-dependent beta-thalassemia. Also, Journavx, a non-opioid drug, is safe and effective for acute pain relief. I view Journavx as a potential blockbuster drug for Vertex.
And this is the part most people miss... Vertex's third growth path could be even bigger than the first two if all goes well: its promising pipeline. The company plans to seek global regulatory approvals next year for zimislecel, a one-time functional cure for severe Type 1 diabetes. The target patient population is around 60,000. They also hope to get FDA accelerated approval in the first half of 2026 for povetacicept to treat IgA nephropathy, a kidney disease affecting 300,000 people in the U.S. and Europe.
But that's not all! Vertex is also evaluating inaxaplin in a phase 3 clinical study targeting APOL1-mediated kidney disease, which affects approximately 250,000 patients. Furthermore, late-stage studies are underway or starting soon to seek additional approvals for Journavx in treating diabetic peripheral neuropathy (affecting over 2 million patients) and povetacicept in treating primary membranous nephropathy (affecting 250,000 patients).
In total, Vertex's programs in clinical testing target indications that affect over 2.75 million patients combined. To put that into perspective, an estimated 109,000 people worldwide have CF.
(Today's Change: 1.36%) Current Price: $425.60
There are two comforting factors that make me feel good about Vertex. First, the company's business is unlikely to be affected by an economic downturn. Vertex has a monopoly in treating the underlying cause of CF, so doctors will continue to prescribe Kaftrio/Trikafta and Alyftrek, regardless of economic conditions. Tariffs should also have a minimal impact.
The second factor is that Vertex isn't facing a patent cliff anytime soon. While key patents for CF therapies Kalydeco and Symdeko/Symkevi expire in 2027, Kaftrio/Trikafta's patents don't expire until 2037. Alyftrek's patents expire in 2039, and Journavx's patents expire in 2040.
One Major Risk for Vertex:
However, like all drugmakers, Vertex faces the risk that its pipeline candidates could fail in clinical testing or fail to get regulatory approval. But I'm not overly concerned about this risk. Vertex has a good track record with late-stage programs, and the company has so many promising candidates that it could weather a setback or two.
Is Vertex Pharmaceuticals bulletproof? Not necessarily. But with a bit of luck, this growth stock should be a big winner in the coming years. What do you think about Vertex? Share your thoughts in the comments below! Do you agree with this assessment, or do you see potential risks that I've overlooked? I'm eager to hear your perspective!
